Vystar Corp (VYST)

[turn144]

Based on the current environment relative to COVID and the fall / winter months ahead, the acceleration of Rx sales is a huge opportunity.

If - and I do mean IF - they can capitalize on the demand and have inventory to meet it - $2 a share will be a steal by Q-1 2022.

Again - they have not been exactly stellar on execution, but if they have enough capital all the other things like mfg, eng, and logistics are in place to take advantage of the opportunity.

GLTU.